Does metformin-associated lactic acidosis really exist? Despite an old controversy, there is no doubt about it. But do we understand what is going on? Laboratory fi ndings raised several hypotheses explaining the pathophysiology of this disease. The main cause could be an inhibition of either gluconeogenesis or mitochondrial respiratory chain complex I. From bench to bedside, one hypothesis is now confi rmed in humans. Metformin poisoning involves, at least partially, a mitochondrial dysfunction.
In this issue of Critical Care, Protti and colleagues [1] report the eff ects of metformin on human platelets both in vitro and ex vivo. In vitro experiments were performed on healthy platelets incubated with increasing doses of metformin, whereas ex vivo experi ments were done on platelets from patients presenting accidental metformininduced lactic acidosis. In both situations, platelets' lactate production and mitochondrial functions were measured. In vitro, a dose-dependent relationship between metformin con cen tration and lactate production was found. In both condi tions, high levels of metformin decreased mito chon drial respiratory chain complex I activity, mitochon dria polarization, and oxygen consump tion. Ex vivo only, mitochondria respiratory chain complex IV activity declined.
Metformin is a biguanide that has been used as a fi rstline drug for type 2 diabetes treatment since 1957 in Europe and 1995 in the US [2] . Metformin was reputed to induce lactic acidosis, partly because phenformin, another biguanide, was withdrawn from the market because of an unacceptable rate of this complication [3] . However, numerous clinical studies reported a similar incidence of lactic acidosis in diabetic patients with or without metformin, leading some authors to deny the existence of metformin-associated lactic acidosis [4] . However, in usual clinical practice, metformin contraindications are not often respected [5] . Moreover, physicians do not really monitor adequately their prescription. As a result, numerous publications reported the asso cia tion between metformin and lactic acidosis [6, 7] . When a cause of lactic acidosis such as shock state or acute renal failure is present, the responsibility of metformin could be questioned. But when healthy patients without risk factors develop metformin poisoning leading to lactic acidosis, there is no doubt about this link. However, metformin inhibits hepatic gluconeogenesis in diff erent animal species and decreases mitochondrial respiratory chain complex I activity in diff erent organs [8, 9] . Both conditions can lead to lactate accumulation. Until recently, the clinical research on metformin-associated lactic acidosis was limited to retrospective studies des crib ing incidence, risk factors, and supportive treatments. A big step forward was made when the Gattinoni group [10] reported a decrease in oxygen consumption after metformin poisoning in humans, strongly suggesting that metformin was able to induce mitochondrial dysfunction in humans. Th e study by Protti and colleagues elegantly confi rms the implication of mitochondria in the pathophysiology of this disease. But it does not rule out the eff ects of metformin on gluconeogenesis. Further research is needed to assess the respective parts of these mechanisms.
Of course, the importance of platelet mitochondrial dysfunction per se has to be put in perspective. Platelets are probably not involved in lactic acidosis build-up during metformin overdose. However, as demonstrated previously in the pig, platelet mitochondrial dysfunction mirrors the mitochondrial dysfunction in other vital organs [11] . Platelets are more easily accessible than vital organs like the liver or kidney. For research purposes in humans, this approach seems to be promising to evaluate the eff ects of potential therapies. However, a possible limit to their fi ndings lies in their model. It is not clear whether this model represents acute or chronic overdose. Th is question is important as they are considered diff erent conditions with diff erent prognoses [12] . Acute intentional poisoning clearly has a better outcome than accidental accumulation. Now that serious research on this rare disease has started, we can also imagine improving its care. Currently, the treatment is only supportive: increasing blood pressure with fl uid infusion and catecholamines and promoting metformin elimination by renal replacement therapy. Restoring ATP production during energy failure due to mitochondria dysfunction is still challenging. New ideas could come from metabolic manipulations. In severe sepsis, another condition associated with mitochondrial dysfunction, succinate can bypass respiratory chain complex I inhibition and restore oxygen consumption [13] . In isolated cells, succinate is reputed not to cross the plasma membrane, but methyl succinate (a cellpermeant succinate) has been used to bypass metformin blockade of respiratory chain complex I [14] . Th is intervention led to a reduction of metformin toxicity. Th is strategy might be a therapeutic modality for metformin overdose in the future.
